Skip to main content

Table 1 Baseline characteristics between micro-nutrient deficiency group and non-deficiency group

From: Incidence and risk factors of micronutrient deficiency in patients with IBD and intestinal Behçet’s disease: folate, vitamin B12, 25-OH-vitamin D, and ferritin

Variables

Total (n = 205)

Micro-nutrient deficiency group (n = 80, 39.0%)

Non-deficiency group (n = 125, 61.0%)

P-value

Male sex

118 (57.6)

44 (55.0)

74 (59.2)

0.553

Age

34 (19–47)

27 (19–41)

37 (20–51)

0.003

The path of laboratory test

   

0.150

 Outpatients clinic

191 (93.2)

72 (90.0)

119 (95.2)

 

 Hospitalization patients

14 (6.8)

8 (10.0)

6 (4.8)

 

Number of micronutrient tests

    

 Folate

127 (62.0)

64 (80.0)

63 (50.4)

 < 0.001

 Vitamin B12

128 (62.4)

64 (80.0)

64 (51.2)

 < 0.001

 25-OH-vitamin D

184 (90.2)

67 (83.8)

117 (94.4)

0.013

 Ferritin

97 (47.3)

48 (60.0)

49 (39.2)

0.004

Type of IBD

   

0.003

 UC

49 (23.9)

9 (11.3)

40 (32.0)

 

 CD

143 (69.8)

66 (82.5)

77 (61.6)

 

 Intestinal BD

13 (6.3)

5 (6.3)

8 (6.4)

 

Medications

    

 5-ASA

114 (55.6)

33 (41.3)

81 (64.8)

0.001

 Steroids

12 (5.9)

3 (3.8)

9 (7.2)

0.305

 Azathioprine

66 (32.2)

32 (40.0)

34 (27.2)

0.056

 Anti-TNF

101 (49.3)

45 (56.3)

56 (44.8)

0.110

 Methotrexate

33 (16.1)

11 (13.8)

22 (17.6)

0.464

 6-MP

2 (1.0)

0 (0)

2 (1.6)

0.256

 Othersa

12 (5.9)

2 (2.5)

10 (8.0)

0.102

Supplementary medications

    

 Iron supplementation

77 (37.6)

43 (53.8)

34 (27.2)

 < 0.001

 Folate supplementation

50 (24.4)

26 (32.5)

24 (19.2)

0.031

 Multivitamin

52 (25.4)

21 (26.3)

31 (24.8)

0.816

 Calcium, Vitamin D supplementation

127 (62.0)

51 (63.7)

76 (60.8)

0.671

 Vitamin B12 supplementation

43 (21.0)

30 (37.5)

13 (10.4)

 < 0.001

 Vitamin C supplementation

3 (1.5)

0 (0)

3 (2.4)

0.163

 Zinc supplementation

7 (3.4)

3 (3.8)

4 (3.2)

0.832

 Osteoporosis medication

    

 SERM

3 (1.5)

1 (1.3)

2 (1.6)

0.839

 Bisphosphonate

14 (6.8)

1 (1.3)

13 (10.4)

0.011

Operation

65 (31.7)

33 (41.3)

32 (25.6)

0.019

Underlying disease

    

 Hypertension

4 (2.0)

1 (1.3)

3 (2.4)

0.561

 Diabetes

1 (0.5)

0 (0)

1 (0.8)

0.423

 Osteoporosis

38 (18.5)

13 (16.3)

25 (20.0)

0.500

 Othersb

46 (22.4)

19 (23.8)

27 (21.6)

0.719

  1. Data are expressed as median (interquartile range, IQR) or n (%). *P-value for comparing patients with micronutrient deficiency group and non-deficiency group
  2. IBD, Inflammatory bowel disease; UC, Ulcerative colitis; CD, Crohn’s disease; BD, Behçet’s disease; 5-ASA, 5-aminosalicylic acid; anti-TNF, anti-tumor necrosis factor; 6-MP, 6-mercaptopurine; SERM, Selective estrogen receptor modulators
  3. aMongersen, vedolizumab
  4. bMyelodysplastic syndrome, Systemic lupus erythematosus, aortic valve disease, Bronchiolitis obliterans with organizing pneumonia, osteoarthritis, coronary artery occlusive disease, cancer
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us